ESPEN guidelines on nutrition in cancer patients J Arends, P Bachmann, V Baracos, N Barthelemy, H Bertz, F Bozzetti, ... Clinical nutrition 36 (1), 11-48, 2017 | 3180 | 2017 |
ESPEN practical guideline: Clinical Nutrition in cancer M Muscaritoli, J Arends, P Bachmann, V Baracos, N Barthelemy, H Bertz, ... Clinical Nutrition 40 (5), 2898-2913, 2021 | 834 | 2021 |
ESPEN Guidelines on Parenteral Nutrition: home parenteral nutrition (HPN) in adult patients M Staun, L Pironi, F Bozzetti, J Baxter, A Forbes, F Joly, P Jeppesen, ... Clinical nutrition 28 (4), 467-479, 2009 | 573 | 2009 |
Nanomedicines: addressing the scientific and regulatory gap S Tinkle, SE McNeil, S Mühlebach, R Bawa, G Borchard, Y Barenholz, ... Annals of the New York Academy of Sciences 1313 (1), 35-56, 2014 | 538 | 2014 |
Nutritional risk is a clinical predictor of postoperative mortality and morbidity in surgery for colorectal cancer I Schwegler, A Von Holzen, JP Gutzwiller, R Schlumpf, S Mühlebach, ... Journal of British Surgery 97 (1), 92-97, 2010 | 494 | 2010 |
ESPEN guideline on home parenteral nutrition L Pironi, K Boeykens, F Bozzetti, F Joly, S Klek, S Lal, M Lichota, ... Clinical nutrition 39 (6), 1645-1666, 2020 | 236 | 2020 |
The therapeutic equivalence of complex drugs H Schellekens, E Klinger, S Mühlebach, JF Brin, G Storm, DJA Crommelin Regulatory Toxicology and Pharmacology 59 (1), 176-183, 2011 | 158 | 2011 |
Managing the patient journey through enteral nutritional care P Howard, C Jonkers-Schuitema, L Furniss, U Kyle, S Muehlebach, ... Clinical nutrition 25 (2), 187-195, 2006 | 140 | 2006 |
How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider H Schellekens, S Stegemann, V Weinstein, JSB de Vlieger, B Flühmann, ... The AAPS journal 16, 15-21, 2014 | 136 | 2014 |
Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach? S Mühlebach Advanced drug delivery reviews 131, 122-131, 2018 | 114 | 2018 |
Nanomedicines: The magic bullets reaching their target? B Flühmann, I Ntai, G Borchard, S Simoens, S Mühlebach European Journal of Pharmaceutical Sciences 128, 73-80, 2019 | 111 | 2019 |
The similarity question for biologicals and non-biological complex drugs DJA Crommelin, VP Shah, I Klebovich, SE McNeil, V Weinstein, ... European Journal of Pharmaceutical Sciences 76, 10-17, 2015 | 97 | 2015 |
Neonatology/paediatrics–Guidelines on parenteral nutrition, Chapter 13 C Fusch, K Bauer, HJ Böhles, F Jochum, B Koletzko, M Krawinkel, ... GMS german medical science 7, 2009 | 92 | 2009 |
Equivalence of complex drug products: advances in and challenges for current regulatory frameworks L Hussaarts, S Mühlebach, VP Shah, S McNeil, G Borchard, B Flühmann, ... Annals of the New York Academy of Sciences 1407 (1), 39-49, 2017 | 83 | 2017 |
Nanoparticle iron medicinal products–Requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies G Borchard, B Flühmann, S Mühlebach Regulatory Toxicology and Pharmacology 64 (2), 324-328, 2012 | 83 | 2012 |
Implementation of treatment guidelines to support judicious use of antibiotic therapy S Deuster, I Roten, S Muehlebach Journal of clinical pharmacy and therapeutics 35 (1), 71-78, 2010 | 80 | 2010 |
Lipid peroxidation of iv lipid emulsions in TPN bags: the influence of tocopherols PJK Steger, SF Mühlebach Nutrition 14 (2), 179-185, 1998 | 80 | 1998 |
Different pharmaceutical products need similar terminology DJA Crommelin, JSB de Vlieger, V Weinstein, S Mühlebach, VP Shah, ... The AAPS journal 16, 11-14, 2014 | 77 | 2014 |
Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars S Mühlebach, G Borchard, S Yildiz Nanomedicine 10 (4), 659-674, 2015 | 70 | 2015 |
Pharmacokinetics in rats of 2, 4, 5, 2′, 4′, 5-hexachlorobiphenyl, an unmetabolizable lipophilic model compound S Mühlebach, MH Bickel Xenobiotica 11 (4), 249-257, 1981 | 68 | 1981 |